Company Profile
Delmont Laboratories is a privately held company that was founded in 1950 by Robert E. Lincoln, MD. The firm relocated to its present location at 715 Harvard Avenue, Swarthmore, PA 19081, in 1952 under the leadership of Charles E Lincoln, the founder?s brother. Subsequently, Delmont was incorporated under the laws of the State of Pennsylvania as a C Corporation. In 1987 the current owners, David J. Ganfield, PhD and his wife Mong Ching Ganfield, PhD, purchased the firm. There are eight employees. Five of the employees have PhD degrees in various life sciences.
Delmont?s Product, Staphage Lysate (SPL)® was licensed for human use in 1959 (NIH Biologics License No. 299) in the United States. There is a large volume of literature published during the past 40 years which deals with various aspects of the use of SPL, a whole bacterial cell lysate produced by bacteriophage, in the treatment of chronic disease. The utility of bacteriophage and the lysates in the treatment of staphylococcal infections was reported by Robert Lincoln, MD in 1948. He also recognized that the staphylococcal phage lysates were particularly useful in the treatment of immune compromised patients and patients with chronic infections. Dr. Lincoln helped found Lincoln Laboratories that is now known as Delmont Laboratories.
In 1986 Delmont Labs, Inc. applied to the U. S. Dept. of Agriculture for a veterinary license for the use of Staphage Lysate (SPL)® in the treatment of canine pyoderma. The USA license was issued in 1987. Delmont Labs, Inc. has subsequently obtained veterinary licenses in Canada (English speaking 1992, French speaking, 2000) and Brazil (2001).
Staphage Lysate (SPL)® is sold through veterinary distributors and directly by contacting Delmont Labs.
